A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling
Constanza Rodriguez, Robert S. Edinger, George Diehl, Jeyshka M. Reyes-González, Woonghee Lee, John Buckley, Jangsuk Oh, Divya Nambiar, Kwamena Baidoo, Reona Okada, Ira Phadke, Zoe Schmiechen, Hannah Khan, Yash Sakhalkar, Angel G. Cortez, Anders Josefsson, Jessie R. Nedrow, Ayla White, Deborah E. Citrin, Xiyuan Zhang, Carolyn J. Anderson, Freddy E. Escorcia, Ravi B. Patel, Rosa Nguyen · 2026
Read A radiopharmaceutical enhances CAR T cells against radio-sensitive and radio-resistant neuroblastoma by tumor sensitization and TME remodeling by Constanza Rodriguez, Robert S. Edinger, George Diehl, Jeyshka M. Reyes-González, Woonghee Lee, John Buckley, Jangsuk Oh, Divya Nambiar, Kwamena Baidoo, Reona Okada, Ira Phadke, Zoe Schmiechen, Hannah Khan, Yash Sakhalkar, Angel G. Cortez, Anders Josefsson, Jessie R. Nedrow, Ayla White, Deborah E. Citrin, Xiyuan Zhang, Carolyn J. Anderson, Freddy E. Escorcia, Ravi B. Patel, Rosa Nguyen (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13400164.txt.
Description
Constanza Rodriguez and colleagues, with senior author Rosa Nguyen, show that a targeted radioactive drug can supercharge CAR T cell therapy against neuroblastoma, in a 2026 preclinical study. The radiopharmaceutical, copper-67 attached to LLP2A, homes to the VLA-4 integrin found on neuroblastoma. It delivers a short-range beta radiation dose over about two and a half days, timed to fade before the engineered T cells arrive.
In radiation-sensitive tumors, the drug killed cancer cells directly and fired up immune pathways, notably TNF-alpha signaling, that activated the T cells in a paracrine relay. In radiation-resistant tumors, killing was minimal, but the radiation remodeled the myeloid compartment of the tumor's surroundings. It fostered niches where cytotoxic CAR T cells, both CD8 and CD4 types bearing granzyme B, could gather and work. The authors present such preconditioning as a general strategy for solid-tumor cell therapy.
Catalog record
| CREATOR | Constanza Rodriguez, Robert S. Edinger, George Diehl, Jeyshka M. Reyes-González, Woonghee Lee, John Buckley, Jangsuk Oh, Divya Nambiar, Kwamena Baidoo, Reona Okada, Ira Phadke, Zoe Schmiechen, Hannah Khan, Yash Sakhalkar, Angel G. Cortez, Anders Josefsson, Jessie R. Nedrow, Ayla White, Deborah E. Citrin, Xiyuan Zhang, Carolyn J. Anderson, Freddy E. Escorcia, Ravi B. Patel, Rosa Nguyen |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 64734 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |